• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Therapeutic benefits of green tea extract on various parameters in non-alcoholic fatty liver disease patients.绿茶提取物对非酒精性脂肪性肝病患者各项参数的治疗益处。
Pak J Med Sci. 2017 Jul-Aug;33(4):931-936. doi: 10.12669/pjms.334.12571.
2
Vildagliptin ameliorates biochemical, metabolic and fatty changes associated with non alcoholic fatty liver disease.维格列汀可改善与非酒精性脂肪性肝病相关的生化、代谢及脂肪变化。
Pak J Med Sci. 2016 Nov-Dec;32(6):1396-1401. doi: 10.12669/pjms.326.11133.
3
Effects of nigella sativa on various parameters in Patients of non-alcoholic fatty liver disease.黑种草对非酒精性脂肪性肝病患者各项参数的影响。
J Ayub Med Coll Abbottabad. 2017 Jul-Sep;29(3):403-407.
4
Efficacy and safety of dietary polyphenol supplementation in the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis.膳食多酚补充剂治疗非酒精性脂肪性肝病的疗效和安全性:系统评价和荟萃分析。
Front Immunol. 2022 Sep 9;13:949746. doi: 10.3389/fimmu.2022.949746. eCollection 2022.
5
The Effect of Green Tea Extract Supplementation on Liver Enzymes in Patients with Nonalcoholic Fatty Liver Disease.补充绿茶提取物对非酒精性脂肪性肝病患者肝脏酶的影响。
Int J Prev Med. 2016 Feb 1;7:28. doi: 10.4103/2008-7802.173051. eCollection 2016.
6
Effect of vitamin D supplementation on various parameters in non-alcoholic fatty liver disease patients.补充维生素D对非酒精性脂肪性肝病患者各项参数的影响。
Pak J Pharm Sci. 2019 May;32(3 Special):1343-1348.
7
Effect of sour tea supplementation on liver enzymes, lipid profile, blood pressure, and antioxidant status in patients with non-alcoholic fatty liver disease: A double-blind randomized controlled clinical trial.酸茶补充剂对非酒精性脂肪肝患者肝酶、血脂谱、血压和抗氧化状态的影响:一项双盲随机对照临床试验。
Phytother Res. 2021 Jan;35(1):477-485. doi: 10.1002/ptr.6826. Epub 2020 Sep 10.
8
The effects of green cardamom on blood glucose indices, lipids, inflammatory factors, paraxonase-1, sirtuin-1, and irisin in patients with nonalcoholic fatty liver disease and obesity: study protocol for a randomized controlled trial.绿小豆蔻对非酒精性脂肪性肝病和肥胖患者血糖指标、血脂、炎症因子、对氧磷酶-1、沉默调节蛋白-1和鸢尾素的影响:一项随机对照试验的研究方案
Trials. 2017 Jun 7;18(1):260. doi: 10.1186/s13063-017-1979-3.
9
Alterations of liver enzymes and lipid profile in response to exhaustive eccentric exercise: vitamin D supplementation trial in overweight females with non-alcoholic fatty liver disease.超重非酒精性脂肪性肝病女性对耗竭性离心运动的肝酶和血脂谱的改变:维生素 D 补充试验。
BMC Gastroenterol. 2022 Aug 5;22(1):372. doi: 10.1186/s12876-022-02457-w.
10
Non-alcoholic fatty liver disease is closely associated with sub-clinical inflammation: a case-control study on Asian Indians in North India.非酒精性脂肪性肝病与亚临床炎症密切相关:一项针对印度北部亚裔人群的病例对照研究。
PLoS One. 2013;8(1):e49286. doi: 10.1371/journal.pone.0049286. Epub 2013 Jan 11.

引用本文的文献

1
Efficacy of dietary polyphenol supplement in patients with non-alcoholic fatty liver disease: a network meta-analysis.膳食多酚补充剂对非酒精性脂肪性肝病患者的疗效:一项网状Meta分析。
Front Nutr. 2025 May 9;12:1582861. doi: 10.3389/fnut.2025.1582861. eCollection 2025.
2
Effects of green tea supplementation on antioxidant status and inflammatory markers in adults: a grade-assessed systematic review and dose-response meta-analysis of randomised controlled trials.补充绿茶对成年人抗氧化状态和炎症标志物的影响:一项经分级评估的随机对照试验系统评价和剂量反应荟萃分析
J Nutr Sci. 2025 Mar 14;14:e25. doi: 10.1017/jns.2025.13. eCollection 2025.
3
Natural Bioactive Compounds in the Management of Type 2 Diabetes and Metabolic (Dysfunction)-Associated Steatotic Liver Disease.天然生物活性化合物在2型糖尿病和代谢(功能障碍)相关脂肪性肝病管理中的应用
Pharmaceuticals (Basel). 2025 Feb 19;18(2):279. doi: 10.3390/ph18020279.
4
Evaluating Bioactive-Substance-Based Interventions for Adults with MASLD: Results from a Systematic Scoping Review.评估基于生物活性物质的干预措施对患有代谢功能障碍相关脂肪性肝病(MASLD)的成年人的影响:一项系统综述的结果
Nutrients. 2025 Jan 26;17(3):453. doi: 10.3390/nu17030453.
5
The Safety and Efficacy of Dietary Epigallocatechin Gallate Supplementation for the Management of Obesity and Non-Alcoholic Fatty Liver Disease: Recent Updates.膳食表没食子儿没食子酸酯补充剂用于治疗肥胖症和非酒精性脂肪性肝病的安全性和有效性:最新进展
Biomedicines. 2025 Jan 15;13(1):206. doi: 10.3390/biomedicines13010206.
6
Polyphenol Intervention Ameliorates Non-Alcoholic Fatty Liver Disease: An Updated Comprehensive Systematic Review.多酚干预改善非酒精性脂肪性肝病:最新综合系统评价
Nutrients. 2024 Nov 29;16(23):4150. doi: 10.3390/nu16234150.
7
Regular Consumption of Green Tea as an Element of Diet Therapy in Drug-Induced Liver Injury (DILI).常规饮用绿茶作为药物性肝损伤(DILI)饮食疗法的一个元素。
Nutrients. 2024 Aug 24;16(17):2837. doi: 10.3390/nu16172837.
8
Natural Products as Hepatoprotective Agents-A Comprehensive Review of Clinical Trials.天然产物作为肝脏保护剂——临床试验的全面综述
Plants (Basel). 2024 Jul 20;13(14):1985. doi: 10.3390/plants13141985.
9
The Role of Antioxidants in the Treatment of Metabolic Dysfunction-Associated Fatty Liver Disease: A Systematic Review.抗氧化剂在代谢功能障碍相关脂肪性肝病治疗中的作用:一项系统评价
Antioxidants (Basel). 2024 Jun 29;13(7):797. doi: 10.3390/antiox13070797.
10
Effect of Green Tea Supplementation on Inflammatory Markers among Patients with Metabolic Syndrome and Related Disorders: A Systematic Review and Meta-Analysis.补充绿茶对代谢综合征及相关疾病患者炎症标志物的影响:一项系统评价与荟萃分析
Prev Nutr Food Sci. 2024 Jun 30;29(2):106-117. doi: 10.3746/pnf.2024.29.2.106.

本文引用的文献

1
Pharmacological management of nonalcoholic fatty liver disease.非酒精性脂肪性肝病的药物治疗
Metabolism. 2016 Aug;65(8):1183-95. doi: 10.1016/j.metabol.2016.04.004. Epub 2016 May 21.
2
The Effect of Green Tea Extract Supplementation on Liver Enzymes in Patients with Nonalcoholic Fatty Liver Disease.补充绿茶提取物对非酒精性脂肪性肝病患者肝脏酶的影响。
Int J Prev Med. 2016 Feb 1;7:28. doi: 10.4103/2008-7802.173051. eCollection 2016.
3
Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.全球非酒精性脂肪性肝病流行病学——患病率、发病率和结局的荟萃分析评估。
Hepatology. 2016 Jul;64(1):73-84. doi: 10.1002/hep.28431. Epub 2016 Feb 22.
4
Green tea extract activates AMPK and ameliorates white adipose tissue metabolic dysfunction induced by obesity.绿茶提取物可激活腺苷酸活化蛋白激酶(AMPK),并改善肥胖诱导的白色脂肪组织代谢功能障碍。
Eur J Nutr. 2016 Oct;55(7):2231-44. doi: 10.1007/s00394-015-1033-8. Epub 2015 Sep 11.
5
Non-alcohol fatty liver disease in Asia: Prevention and planning.亚洲的非酒精性脂肪性肝病:预防与规划
World J Hepatol. 2015 Jul 8;7(13):1788-96. doi: 10.4254/wjh.v7.i13.1788.
6
Therapeutic effect of high-dose green tea extract on weight reduction: A randomized, double-blind, placebo-controlled clinical trial.高剂量绿茶提取物对体重减轻的治疗效果:一项随机、双盲、安慰剂对照临床试验。
Clin Nutr. 2016 Jun;35(3):592-9. doi: 10.1016/j.clnu.2015.05.003. Epub 2015 May 29.
7
NAFLD: a multisystem disease.非酒精性脂肪性肝病:一种多系统疾病。
J Hepatol. 2015 Apr;62(1 Suppl):S47-64. doi: 10.1016/j.jhep.2014.12.012.
8
Green tea polyphenol epigallocatechin-3-gallate ameliorates insulin resistance in non-alcoholic fatty liver disease mice.绿茶多酚表没食子儿茶素-3-没食子酸酯改善非酒精性脂肪性肝病小鼠的胰岛素抵抗。
Acta Pharmacol Sin. 2015 May;36(5):597-605. doi: 10.1038/aps.2015.11. Epub 2015 Apr 20.
9
Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis.通过生活方式改变减轻体重可显著改善非酒精性脂肪性肝炎的特征。
Gastroenterology. 2015 Aug;149(2):367-78.e5; quiz e14-5. doi: 10.1053/j.gastro.2015.04.005. Epub 2015 Apr 10.
10
The effect of bioactive compounds in tea on lipid metabolism and obesity through regulation of peroxisome proliferator-activated receptors.茶中的生物活性化合物通过调节过氧化物酶体增殖物激活受体对脂质代谢和肥胖的影响。
Curr Opin Lipidol. 2015 Feb;26(1):3-9. doi: 10.1097/MOL.0000000000000145.

绿茶提取物对非酒精性脂肪性肝病患者各项参数的治疗益处。

Therapeutic benefits of green tea extract on various parameters in non-alcoholic fatty liver disease patients.

作者信息

Hussain Mazhar, Akhtar Lubna

机构信息

Dr. Mazhar Hussain, MBBS, M.Phil (Pharmacology), Department of Pharmacology & TherapeuticsSheikh Zayed Medical College, Rahim Yar Khan, Punjab, Pakistan.

Dr. Habib-Ur-Rehman, MBBS, MD, FCPS (Medicine), Department of Medicine, Sheikh Zayed Medical College & Hospital, Rahim Yar Khan, Punjab, Pakistan.

出版信息

Pak J Med Sci. 2017 Jul-Aug;33(4):931-936. doi: 10.12669/pjms.334.12571.

DOI:10.12669/pjms.334.12571
PMID:29067068
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5648967/
Abstract

BACKGROUND AND OBJECTIVE

NAFLD affecting up to 30% of the population globally. Drug treatment options are limited with disappointing results. The dietary supplementation in the form of green tea is another option. Our objective was toinvestigate the effect of Green tea extract (GTE) supplementation on various parameters innon-alcoholicfatty liver disease (NAFLD) patients.

METHODS

This study was conducted Dept. of Medicineof Sheikh Zayed Medical College/Hospital, Rahim Yar Khan from 15 April 2016 to 15 July 2016. Eighty overweight, non diabeticand dyslipidemic patients of NAFLD, diagnosed on the basis of ultrasound and aminotransferases level were randomized for treatmentwith capsule GTE500mg (n=40)and capsule placebo (n=40) twice a day for twelve weeks. Anthropometric parameters, liver enzymes, inflammatory markers and liver ultrasound imaging were estimated by SPSS-16 pre and post treatment.

RESULTS

As compared to placebo, GTE caused a significant improvement in body weight (29.5±3.8 to 27.2±3.2 kg/m p=0.03), BMI (86±10.5 to 80±12.4 kg p=0.026), HOMA-IR(4.32±2.25 to 3.16± 1.6 p=0.0081) lipid profile (i.e. TC: L242.5±20.5 to 215.4±18.6 mg/dl p=0.005; TG: 175±22.6 to145±18 mg/dlp=0.003; LDL-C:155±12.5 to 140±16.7 mg/dl p=0.011; HDL-C: 36.8±6.7 to46.4±5.8 mg/dl p =0.001, Aminotransferases (i.e. ALT: 70.4±15.8to52.8±12.2 IU/L p=0.04; AST: 65.8±12.4 to 44.3± 8.5U/L p =0.002) and Inflammatory markers (hs-CRP: 3.14±0.58 to 2.18±0.32 p =0.023 Adiponectin: 8.46±1.02 to 10.55±3.42μg/ml p =0.003)GTE also caused a 67.5% regression of fatty liver changes on ultrasound as compared to placebo which is 25%only.

CONCLUSION

GTEtherapy resulted in significant improvement in metabolic, chemical, inflammatory and radiological parameters of non-alcoholic fatty liver disease patients who were non-diabetic anddyslipidemic.

摘要

背景与目的

非酒精性脂肪性肝病(NAFLD)影响着全球高达30%的人口。药物治疗选择有限且效果不佳。绿茶形式的膳食补充是另一种选择。我们的目的是研究绿茶提取物(GTE)补充剂对非酒精性脂肪性肝病(NAFLD)患者各项参数的影响。

方法

本研究于2016年4月15日至2016年7月15日在拉希姆亚尔汗谢赫扎耶德医学院/医院内科进行。80名超重、非糖尿病且血脂异常的NAFLD患者,根据超声和转氨酶水平诊断,被随机分为两组,分别接受500毫克GTE胶囊(n = 40)和安慰剂胶囊(n = 40)治疗,每天两次,持续12周。在治疗前后通过SPSS - 16评估人体测量参数、肝酶、炎症标志物和肝脏超声成像。

结果

与安慰剂相比,GTE使体重(从29.5±3.8降至27.2±3.2 kg/m,p = 0.03)、BMI(从86±10.5降至80±12.4 kg,p = 0.026)、HOMA - IR(从4.32±2.25降至3.16±1.6,p = 0.0081)、血脂谱(即总胆固醇:从242.5±20.5降至215.4±18.6 mg/dl,p = 0.005;甘油三酯:从175±22.6降至145±18 mg/dl,p = 0.003;低密度脂蛋白胆固醇:从155±12.5降至140±16.7 mg/dl,p = 0.011;高密度脂蛋白胆固醇:从36.8±6.7升至46.4±5.8 mg/dl,p = 0.001)、转氨酶(即谷丙转氨酶:从70.4±15.8降至52.8±12.2 IU/L,p = 0.04;谷草转氨酶:从65.8±12.4降至44.3±8.5 U/L,p = 0.002)和炎症标志物(高敏C反应蛋白:从3.14±0.58降至2.18±0.32,p = 0.023;脂联素:从8.46±1.02升至10.55±3.42μg/ml,p = 0.003)有显著改善。与安慰剂相比,GTE还使超声检查显示的脂肪肝变化消退了67.5%,而安慰剂组仅为25%。

结论

GTE治疗使非糖尿病且血脂异常的非酒精性脂肪性肝病患者的代谢、生化、炎症和放射学参数有显著改善。